Evec was established in January 2003 with the aim to materialize the technique “to develop human antibodies by using EB virus”, which comes from the 30 years research work of Dr. Kenzo Takada, Professor, Institute for Genetic Medicine, Hokkaido Univieristy (Evec Chairman of the Board). The most outstanding feature is that Evec can develop fully human antibodies by the purely Japanese technique.
Since its establishment, Evec has been operating with mottos to contribute to the health and welfare of people in a wide range of the world with our creative and advanced techniques” and “to activate the industrial world of northern Japan, Hokkaido with our flexible and creative spirit and progressive actions”.

Evec’s ideal is to overcome currently intractable diseases and to provide less costly medicine to patients, high in effects and weak in side-effects. Evec’s antibodies are highly effective, and contribute to reduce medical cost for patients and improve the financial management of health insurance considerably. Evec takes the business model that its allied major pharmaceuticals of the world will launch therapeutic antibodies into the market.

In this business model, Evec specializes in developing fully human antibodies, and its allied pharmaceuticals will perform clinical development and apply for medical approval in respective countries. In the most competitive antibody business world, Evec will accumulate development and advancement of the techniques to establish them as virtually a standard method to replace the currently major technique of using mice etc., and to provide high-quality antibodies to the world from Japan.